A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With Recurrent WHO Grade II Gliomas
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Poly ICLC (Primary) ; SL 701 (Primary)
- Indications Astrocytoma; Oligodendroglioma
- Focus Adverse reactions
- 12 Jul 2017 New trial record
- 06 Jan 2012 Status changed from recruiting to active, not recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov